Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438600 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2CA12CA9POLBMMP2 | |
| SCHEMBL2438598 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2MMP2MMP9 | |
| SCHEMBL3186877 | 0.82 | KMT2A (0.48) | SMN1; SMN2KMT2ACA12CA9POLB | |
| SCHEMBL3186901 | 0.82 | KMT2A (0.48) | SMN1; SMN2KMT2ACA12CA9POLB | |
| SCHEMBL8489619 | 0.81 | CA12 (0.47) | SMN1; SMN2KMT2ACA12CA9POLB | |
| SCHEMBL8489201 | 0.78 | MMP2 (0.43) | SMN1; SMN2CA12CA9POLBMMP2 | |
| SCHEMBL2909670 | 0.77 | CYP3A4 (0.51) | SMN1; SMN2KMT2ACA12CA9POLB | |
| SCHEMBL1058567 | 0.76 | MMP9 (0.40) | KMT2APOLBMMP2MMP9HDAC1 | |
| SCHEMBL8489260 | 0.76 | HDAC7 (0.47) | SMN1; SMN2MMP2MMP9HDAC1HDAC7 | |
| SCHEMBL4750336 | 0.76 | GLS (0.50) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | SMN1; SMN2 4019/4885KMT2A 2273/4885CA12 3467/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | SMN1; SMN2 4444/4885KMT2A 4151/4885CA12 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.